The study found:
• Cologuard detected 92 percent of colorectal cancer, compared to 74 percent in FIT
• Cologuard detected 93 percent of colorectal cancers in Stages I-III, while FIT detected 73 percent
• Cologuard demonstrated a 42 percent sensitivity level in patients with advanced precancerous lesions, while FIT demonstrated 24 percent sensitivity
• Cologuard detected 69 percent of patients with high-grade dysplasia polyps, while FIT detected 46 percent
• Cologuard had a specificity of 87 percent, while FIT had specificity of 95 percent
The results of the study were published in the New England Journal of Medicine.
More Articles on Gastroenterology:
ACG Partners With National Colorectal Cancer Roundtable to Works Toward ’80 by 2018′ Goal
28 Statistics on Colonoscopy Indications
10-Year Stretta Outcomes for GERD Treatment: Q&A With Dr. Mark Noar
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.